Print Magazine
Brussels Morning Newspaper
Thursday, March 23, 2023
No Result
View All Result
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Sustainable Perspective
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Newspaper
  • Home
    • About Us
  • EU institutions
    • Commission
    • Parliament
    • Council
  • Europe
  • World
  • Economy
  • Culture and Society
  • In Depth
    • Ambassador’s Corner
    • The American Angle
    • Sustainable Perspective
    • Europe With Transparency
    • Place de la Bourse
    • The Macro-Economist
    • Southeast Europe
Brussels Morning Newspaper
No Result
View All Result
Home Europe

Italian firm ReiThera in early talks to supply corona vaccine to EU

Nikola Kiš by Nikola Kiš
22 September 2020
in Europe, Features
Italian firm ReiThera in early talks to supply corona vaccine to EU
Share on FacebookShare on Twitter

ReiThera, the Italian biotech company, is in early talks to supply the EU with the coronavirus vaccine it is currently developing, according to unnamed sources cited by Reuters. Reportedly, negotiations are in the initial stages and the outcome remains unclear.

The talks represent the latest attempt by the EU to secure a vaccine, with Brussels seeking to raise more money in order to secure adequate supplies of a vaccine and assuage concerns that demand could exceed supply in 2021. ReiThera is developing a vaccine in cooperation with Germany’s Leukocare and Belgium’s Univercells. 

This latest endeavour brings the number of vaccine makers the European Commission (EC) is negotiating with to a total of seven. The EC has deals with the French company Sanofi to buy up to 300 million doses and with the UK’s AstraZeneca for up to 400 million doses.

The vaccine being developed by ReiThera draws on the same technology used in the AstraZeneca and Johnson & Johnson vaccines. It is currently being tested on 90 volunteers in Italy as part of a phase I study. Results are expected by the end of 2020. Depending on the outcome, the next phase will start in late 2020 in countries with high infection rates.

Keeping in mind the negative effects of lockdowns in the EU, member states are desperate to avoid imposing severe measures yet again, DW reports. France is responding to the recent upsurge of the virus by tightening restrictions in hotspots including Paris, Marseille, Toulouse, Nice and Bordeaux in its efforts not to resort to a second nationwide lockdown. In Spain, Madrid imposed strict restrictions on Monday, while Germany and the UK are considering the possibility of localized lockdowns, depending on the outcome of epidemiologic trends.

According to the World Health Organisation (WHO), the number of new cases per day in Europe stands between 40,000 and 50,000.

SOURCE

Tweets by EU_Commission
Tweets by AstraZeneca
Tweets by JNJNews
Tweets by WHO
Tags: EUItalyVaccine
Facebook Twitter Youtube LinkedIn

About Us

Brussels Morning is a daily online newspaper based in Belgium. BM publishes unique and independent coverage on international and European affairs. With a Europe-wide perspective, BM covers policies and politics of the EU, significant Member State developments, and looks at the international agenda with a European perspective.

Category

  • Ambassador’s Corner
  • Belgium News
  • Brussels
  • Commission
  • Council
  • Culture and Society
  • Diplomacy
  • Economy
  • EU Institutions
  • Europe
  • Europe With Transparency
  • Features
  • Health & Fitness
  • In Depth
  • Member States
  • Middle East Eye
  • Opinion
  • Our pick
  • Parliament
  • Place de la Bourse
  • Southeast Europe
  • Sustainable Perspective
  • The American Angle
  • The Macro-Economist
  • Uncategorised
  • US Elections
  • World

More info

  • About Us
  • Advertising
  • Cookies Policy
  • Contact Us
  • FAQ
  • Jobs

Brussels Morning Newspaper - All Rights Reserved © 2020

No Result
View All Result
  • Home
  • About Us
  • Brussels Bubble
    • Parliament
    • Commission
    • Council
  • Wider Europe
    • Member States
  • World
  • Business & Society
  • Europe With Transparency
  • Culture & Society
  • Policy Talks
    • Place de la Bourse
    • The Macro-Economist
    • Sustainable Perspective
    • Ambassador’s Corner
    • The American Angle
    • Southeast Europe
  • Print Magazine

Brussels Morning Newspaper - All Rights Reserved © 2020

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT